BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096 [PMID: 36246814 DOI: 10.12998/wjcc.v10.i28.10085]
URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm
Number Citing Articles
1
Sheila F. Lumley, Marion Delphin, Jolynne F. Mokaya, Cedric C.S. Tan, Emily Martyn, Motswedi Anderson, Ka Chun Li, Elizabeth Waddilove, Gloria Sukali, Louise O. Downs, Khadija Said, Dorcas Okanda, Cori Campbell, Eli Harriss, Yusuke Shimakawa, Philippa C. Matthews. A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovirJournal of Clinical Virology 2024; 174: 105711 doi: 10.1016/j.jcv.2024.105711
2
Alexander J Stockdale, Bethany Holt, Ajeet Singh Bhadoria, Abhishek Sadasivan, Daniel Ikeda, Todd Pollack, Janus P Ong, Thuy Pham, David B Duong, Vy Nguyen, Gibril Ndow, Roger Chou, Philippa Easterbrook. Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology 2025;  doi: 10.1016/S2468-1253(25)00163-3